uniQure NV (QURE) Shares Down 1.5%
uniQure NV (NASDAQ:QURE) shares dropped 1.5% during trading on Friday . The stock traded as low as $7.22 and last traded at $7.26, with a volume of 96,100 shares. The stock had previously closed at $7.37.
QURE has been the subject of several analyst reports. Piper Jaffray Cos. reiterated an “overweight” rating and set a $26.00 price target on shares of uniQure NV in a report on Tuesday, April 5th. Oppenheimer Holdings Inc. reiterated a “buy” rating and set a $23.00 price target (down previously from $50.00) on shares of uniQure NV in a report on Tuesday, April 5th. Jefferies Group reiterated a “buy” rating on shares of uniQure NV in a report on Wednesday, April 6th. Leerink Swann restated a “buy” rating and set a $27.00 price objective (down previously from $48.00) on shares of uniQure NV in a research report on Wednesday, April 13th. Finally, Chardan Capital restated a “buy” rating on shares of uniQure NV in a research report on Thursday, April 14th. One analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. uniQure NV has a consensus rating of “Buy” and an average target price of $30.80.
The firm’s market capitalization is $177.95 million. The company’s 50 day moving average is $8.75 and its 200-day moving average is $12.69.
uniQure NV (NASDAQ:QURE) last posted its quarterly earnings results on Tuesday, May 31st. The company reported ($0.93) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.82) by $0.10. Analysts forecast that uniQure NV will post ($3.44) earnings per share for the current year.
Uniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.